Prothena EPS - Earnings per Share 2011-2022 | PRTA

Prothena eps - earnings per share from 2011 to 2022. Eps - earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
Prothena Annual EPS
2021 $1.38
2020 $-2.78
2019 $-1.95
2018 $-3.93
2017 $-4.07
2016 $-4.66
2015 $-2.66
2014 $-0.29
2013 $-2.20
2012 $-2.84
2011 $-2.05
2010 $-0.86
Prothena Quarterly EPS
2022-03-31 $-0.78
2021-12-31 $-0.42
2021-09-30 $2.13
2021-06-30 $0.58
2021-03-31 $-0.91
2020-12-31 $-0.76
2020-09-30 $-0.77
2020-06-30 $-0.66
2020-03-31 $-0.59
2019-12-31 $-0.54
2019-09-30 $-0.49
2019-06-30 $-0.40
2019-03-31 $-0.52
2018-12-31 $-0.55
2018-09-30 $-0.62
2018-06-30 $-1.50
2018-03-31 $-1.26
2017-12-31 $-1.25
2017-09-30 $-1.37
2017-06-30 $-0.46
2017-03-31 $-0.99
2016-12-31 $-1.41
2016-09-30 $-1.26
2016-06-30 $-1.18
2016-03-31 $-0.81
2015-12-31 $-0.79
2015-09-30 $-0.73
2015-06-30 $-0.59
2015-03-31 $-0.55
2014-12-31 $-0.65
2014-09-30 $-0.48
2014-06-30 $0.06
2014-03-31 $0.78
2013-12-31 $-0.50
2013-09-30 $-0.55
2013-06-30 $-0.64
2013-03-31 $-0.51
2012-12-31 $-0.82
2012-09-30 $-0.60
2012-06-30 $-0.67
2012-03-31 $-0.75
2011-12-31 $0.00
2010-12-31 $0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.198B $0.201B
Prothena Corp. plc, being a clinical-stage neuroscience company, focused on the development of novel therapeutic therapies for life-threatening diseases. Its wholly owned programs include birtamimab for the potential treatment of AL amyloidosis, PRX004 for the potential treatment of ATTR amyloidosis and a portfolio of programs for the potential treatment of Alzheimer's disease including PRX012 that targets A?.?Prothena is also developing candidates in collaboration with bigwigs like Roche and Bristol-Myers Squibb. These programs include prasinezumab, in collaboration with Roche for the potential treatment of Parkinson's disease and other related synucleinopathies, and programs that target tau, TDP-43 and an undisclosed target in collaboration with Bristol-Myers Squibb for the potential treatment of Alzheimer's disease, amyotrophic lateralsclerosis, etc. It sold PRX004 and the broader ATTR amyloidosis program to Novo Nordisk. It derives revenues from license, development & commercialization agreements.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.981B 9.98
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
Biohaven Pharmaceutical Holding (BHVN) United States $9.996B 0.00
QIAGEN (QGEN) Netherlands $9.982B 15.76
Ginkgo Bioworks Holdings (DNA) United States $4.276B 0.00
Emergent Biosolutions (EBS) United States $1.424B 6.09
Arcus Biosciences (RCUS) United States $1.353B 34.31
Myovant Sciences (MYOV) United Kingdom $0.930B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.444B 0.00
Gelesis Holdings (GLS) United States $0.355B 0.00
Zymeworks (ZYME) Canada $0.299B 0.00
Ambrx Biopharma (AMAM) United States $0.138B 0.00
Enzo Biochem (ENZ) United States $0.118B 24.20
SQZ Biotechnologies (SQZ) United States $0.090B 0.00